Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors

Journal of Biological Chemistry

Volumn 288, Issue 23, 2013, Pages 16334-16347

  Stehle, Franziska ^a   Schulz, Kristin ^a   Fahldieck, Corinna ^a   Kalich, Jana ^a   Lichtenfels, Rudolf ^a   Riemann, Dagmar ^a   Seliger, Barbara ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCTION; APOPTOTIC MECHANISMS; CELL-CYCLE PROGRESSION; COMPARATIVE ANALYSIS; IMMUNE EFFECTOR CELLS; MITOCHONDRIAL MEMBRANE POTENTIAL; MYELOID LEUKEMIA; TYROSINE KINASE INHIBITOR;

AMINO ACIDS; CELL PROLIFERATION; DISEASES; ENZYMES; PATIENT TREATMENT; T-CELLS;

CELL DEATH;

AXITINIB; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; DIPEPTIDYL PEPTIDASE IV; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN MCL 1; SORAFENIB; SUNITINIB;

APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL CYCLE PROGRESSION; CELL VIABILITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EFFECTOR CELL; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

APOPTOSIS; AXITINIB; IMMUNOLOGY; IMMUNOSUPPRESSION; IMMUNOTHERAPY; SORAFENIB; SUNITINIB; T CELL; TARGETED THERAPY; TYROSINE KINASE INHIBITOR;

ANTIGENS, CD; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; IMIDAZOLES; IMMUNOSUPPRESSIVE AGENTS; INDAZOLES; JURKAT CELLS; M PHASE CELL CYCLE CHECKPOINTS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CCR7; RECEPTORS, CXCR3;

EID: 84878758972     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.437962     Document Type: Article

References (54)

1. Flanigan, R. C., Campbell, S. C., Clark, J. I., and Picken, M. M. (2003) Metastatic renal cell carcinoma. Curr. Treat. Options Oncol. 4, 385-390
2. Naito, S., Koga, H., Yokomizo, A., Sakamoto, N., Kotoh, S., Nakashima, M., Kiue, A., and Kuwano, M. (2000) Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas. World J. Surg. 24, 1183-1186
3. Thompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., and Kwon, E. D. (2007) PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 13, 1757-1761 (Pubitemid 46952942)
4. Porta, C., Bonomi, L., Lillaz, B., Paglino, C., Rovati, B., Imarisio, I., Morbini, P., Villa, C., Danova, M., Mensi, M., and Rovereto, B. (2007) Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Anticancer Res. 27, 165-173
5. Gouttefangeas, C., Stenzl, A., Stevanović, S., and Rammensee, H. G. (2007) Immunotherapy of renal cell carcinoma. Cancer Immunol. Immunother. 56, 117-128 (Pubitemid 44812454)
6. Seliger, B., Massa, C., Rini, B., Ko, J., and Finke, J. (2010) Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. Trends Mol. Med. 16, 184-192
7. Hutson, T. E. (2011) Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 16, Suppl. 2, 14-22
8. Finke, J., Ko, J., Rini, B., Rayman, P., Ireland, J., and Cohen, P. (2011)MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 11, 856-861
9. Rini, B. I., and Atkins, M. B. (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 10, 992-1000
10. Li, B., Lalani, A. S., Harding, T. C., Luan, B., Koprivnikar, K., Huan Tu, G., Prell, R., VanRoey, M. J., Simmons, A. D., and Jooss, K. (2006) Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12, 6808-6816 (Pubitemid 44876851)
11. Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L. P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., and Coukos, G. (2011) Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475, 226-230
12. Chouaib, S., Messai, Y., Couve, S., Escudier, B., Hasmim, M., and Noman, M. Z. (2012) Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front. Immunol. 3, 21
13. Porta, C., Paglino, C., Imarisio, I., Ganini, C., and Pedrazzoli, P. (2011) Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J. Cancer 2, 333-338
14. Jonasch, E., Corn, P., Pagliaro, L. C., Warneke, C. L., Johnson, M. M., Tamboli, P., Ng, C., Aparicio, A., Ashe, R. G., Wright, J. J., and Tannir, N. M. (2010) Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon α in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116, 57-65
15. Procopio, G., Verzoni, E., Bracarda, S., Ricci, S., Sacco, C., Ridolfi, L., Porta, C., Miceli, R., Zilembo, N., and Bajetta, E. (2011) Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br. J. Cancer 104, 1256-1261
16. Biswas, S., and Eisen, T. (2009) Immunotherapeutic strategies in kidney cancer-when TKIs are not enough. Nat. Rev. Clin. Oncol. 6, 478-487
17. Pozarowski, P., and Darzynkiewicz, Z. (2004) Analysis of cell cycle by flow cytometry. Methods Mol. Biol. 281, 301-311
18. Leich, F., Stöhr, N., Rietz, A., Ulbrich-Hofmann, R., and Arnold, U. (2007) Endocytotic internalization as a crucial factor for the cytotoxicity of ribonucleases. J. Biol. Chem. 282, 27640-27646 (Pubitemid 47529500)
19. Hengartner, M. O. (2000) The biochemistry of apoptosis. Nature 407, 770-776
20. Gu, Y., Zhao, W., Meng, F., Qu, B., Zhu, X., Sun, Y., Shu, Y., and Xu, Q. (2010) Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. Clin. Immunol. 135, 55-62
21. Flörcken, A., Takvorian, A., Van Lessen, A., Singh, A., Hopfenmüller, W., Dörken, B., Pezzutto, A., and Westermann, J. (2012) Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma. Anticancer Drugs 23, 298-302
22. Zhao, W., Gu, Y. H., Song, R., Qu, B. Q., and Xu, Q. (2008) Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 22, 1226-1233 (Pubitemid 351833791)
23. Bose, A., Lowe, D. B., Rao, A., and Storkus, W. J. (2012) Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res. 22, 236-243
24. Zhou, X., Zheng, M., Chen, F., Zhu, Y., Yong, W., Lin, H., Sun, Y., and Han, X. (2009) Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest. Anat. Rec. 292, 1122-1127
25. Minkin, P., Zhao, M., Chen, Z., Ouwerkerk, J., Gelderblom, H., and Baker, S. D. (2008) Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 874, 84-88
26. Awada, A., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M., de Valeriola, D., Strumberg, D., Brendel, E., Haase, C. G., Schwartz, B., and Piccart, M. (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer 92, 1855-1861 (Pubitemid 40826133)
27. Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., Schwartz, B., Awada, A., Voigtmann, R., Scheulen, M. E., and Seeber, S. (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23, 965-972 (Pubitemid 46202316)
28. Sharma, S., Abhyankar, V., Burgess, R. E., Infante, J., Trowbridge, R. C., Tarazi, J., Kim, S., Tortorici, M., Chen, Y., and Robles, R. L. (2010) A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann. Oncol. 21, 297-304
29. Rugo, H. S., Herbst, R. S., Liu, G., Park, J. W., Kies, M. S., Steinfeldt, H. M., Pithavala, Y. K., Reich, S. D., Freddo, J. L., and Wilding, G. (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 23, 5474-5483
30. Hipp, M. M., Hilf, N., Walter, S., Werth, D., Brauer, K. M., Radsak, M. P., Weinschenk, T., Singh-Jasuja, H., and Brossart, P. (2008) Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111, 5610-5620
31. Bromley, S. K., Thomas, S. Y., and Luster, A. D. (2005) Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat. Immunol. 6, 895-901 (Pubitemid 43090444)
32. Dar, W. A., and Knechtle, S. J. (2007) CXCR3-mediated T-cell chemotaxis involves ZAP-70 and is regulated by signalling through the T-cell receptor. Immunology 120, 467-485 (Pubitemid 46365016)
33. Mohan, K., Cordeiro, E., Vaci, M., McMaster, C., and Issekutz, T. B. (2005) CXCR3 is required for migration to dermal inflammation by normal and in vivo activated T cells: differential requirements by CD4 and CD8 memory subsets. Eur. J. Immunol. 35, 1702-1711 (Pubitemid 40862318)
34. De Meester, I., Korom, S., Van Damme, J., and Scharpé, S. (1999) CD26, let it cut or cut it down. Immunol. Today 20, 367-375 (Pubitemid 29356431)
35. Bühling, F., Kunz, D., Reinhold, D., Ulmer, A. J., Ernst, M., Flad, H. D., and Ansorge, S. (1994) Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. Nat. Immun. 13, 270-279 (Pubitemid 24326646)
36. Chen, M. L., Pittet, M. J., Gorelik, L., Flavell, R. A., Weissleder, R., von Boehmer, H., and Khazaie, K. (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF- signals in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 419-424 (Pubitemid 40116782)
37. Liotta, F., Gacci, M., Frosali, F., Querci, V., Vittori, G., Lapini, A., Santarlasci, V., Serni, S., Cosmi, L., Maggi, L., Angeli, R., Mazzinghi, B., Romagnani, P., Maggi, E., Carini, M., Romagnani, S., and Annunziato, F. (2011) Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 107, 1500-1506
38. Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P. Y., and Chen, S. H. (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69, 2514-2522
39. Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., Dreicer, R., Bukowski, R., and Finke, J. H. (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15, 2148-2157
40. Xin, H., Zhang, C., Herrmann, A., Du, Y., Figlin, R., and Yu, H. (2009) Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69, 2506-2513
41. Finke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., and Bukowski, R. (2008) Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 14, 6674-6682
42. Sohn, D., Schulze-Osthoff, K., and Jänicke, R. U. (2005) Caspase-8 can be activated by interchain proteolysis without receptor-triggered dimerization during drug-induced apoptosis. J. Biol. Chem. 280, 5267-5273 (Pubitemid 40279999)
43. Samraj, A. K., Sohn, D., Schulze-Osthoff, K., and Schmitz, I. (2007) Loss of caspase-9 reveals its essential role for caspase-2 activation and mitochondrial membrane depolarization. Mol. Biol. Cell 18, 84-93 (Pubitemid 46066713)
44. Vander Heiden, M. G., Chandel, N. S., Williamson, E. K., Schumacker, P. T., and Thompson, C. B. (1997) Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell 91, 627-637 (Pubitemid 27513654)
45. Andersen, J. L., and Kornbluth, S. (2012) Mcl-1 rescues a glitch in the matrix. Nat. Cell Biol. 14, 563-565
46. Rahmani, M., Davis, E. M., Bauer, C., Dent, P., and Grant, S. (2005) Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 280, 35217-35227 (Pubitemid 41532709)
47. Rahmani, M., Davis, E. M., Crabtree, T. R., Habibi, J. R., Nguyen, T. K., Dent, P., and Grant, S. (2007) The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol. Cell. Biol. 27, 5499-5513 (Pubitemid 47124402)
48. Yu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A., Kaufmann, S. H., and Adjei, A. A. (2005) The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24, 6861-6869 (Pubitemid 41509409)
49. Harley, M. E., Allan, L. A., Sanderson, H. S., and Clarke, P. R. (2010) Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J. 29, 2407-2420
50. Hwang, A., Maity, A., McKenna, W. G., and Muschel, R. J. (1995) Cell cycle-dependent regulation of the cyclin B1 promoter. J. Biol. Chem. 270, 28419-28424
51. Allan, L. A., and Clarke, P. R. (2007) Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol. Cell 26, 301-310 (Pubitemid 46617338)
52. Bose, A., Taylor, J. L., Alber, S., Watkins, S. C., Garcia, J. A., Rini, B. I., Ko, J. S., Cohen, P. A., Finke, J. H., and Storkus, W. J. (2011) Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int. J. Cancer 129, 2158-2170
53. Farsaci, B., Higgins, J. P., and Hodge, J. W. (2012) Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int. J. Cancer 130, 1948-1959
54. Kujawski, M., Zhang, C., Herrmann, A., Reckamp, K., Scuto, A., Jensen, M., Deng, J., Forman, S., Figlin, R., and Yu, H. (2010) Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res. 70, 9599-9610